Cell Therapeutics' (CTIC +5.9%) pacritinib drug showed encouraging anti-tumor activity and good...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor

Cell Therapeutics' (CTIC +5.9%) pacritinib drug showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed or refractory lymphoma in a Phase I trial. Pacritinib has already performed well in Phase II studies for patients with myelofibrosis, and the company intends to carry out Phase III trials for this bone-marrow illness. (PR)